Three oncology biotechs flagged with under 18 months cash runway

BIO 360's burn-rate model flags three oncology names with narrowing runways — each carrying a mid-stage asset the market has not fully priced.

BIO 360's burn-rate model has flagged three oncology biotechs with fewer than 18 months of cash runway as of the most recent quarterly filing. All three carry mid- to late-stage assets in competitive indications, making them potential candidates for licensing deals, strategic partnerships, or distressed-asset acquisition ahead of the next financing window.

The flagging pattern — declining cash reserves combined with a Phase II readout window in the next two quarters — historically correlates with an increased probability of a licensing or acquisition event within 12 months. Full company profiles, pipeline details, and runway modelling are available in BIO 360.